D.E. Shaw & Co
APTO

D.E. Shaw & Co’s Aptose Biosciences, Inc. APTO Stock Holding History

D.E. Shaw & Co’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-174
Closed -$58K – 5691
2022
Q2 		$58K Sell
174
-610
-78% -$292K ﹤0.01% 4823
2022
Q1 		$480K Buy
784
+197
+34% +$109K ﹤0.01% 4400
2021
Q4 		$357K Buy
+587
New +$552K ﹤0.01% 4593

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

D.E. Shaw & Co's APTO Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Aptose Biosciences, Inc. (APTO) in Q3 2022, closing a stake of 174 shares — an estimated $58K sold.

D.E. Shaw & Co first reported a position in APTO in Q4 2021 and held it in 3 quarters. The position peaked at $480K in Q1 2022. 49 funds tracked by Wall St. Rank hold APTO as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Aptose Biosciences, Inc. position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 174 Aptose Biosciences, Inc. shares in Q3 2022, an estimated $58K.
  • D.E. Shaw & Co first reported a position in Aptose Biosciences, Inc. in Q4 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Aptose Biosciences, Inc. position peaked at $480K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.